Three times as many deaths in the study arm versus the control arm in a trial of ADC Therapeutics' Zynlonta have raised ...

In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in ...

ADC Therapeutics (ADCT) stock plunged as confirmatory late-stage trial data for the company's lymphoma therapy Zynlonta ...

Shares for ADC Therapeutics fell more than 50% after a Phase 3 trial observed a death rate that at least one analyst believes ...

June 4 (Reuters) - ADC Therapeutics shares slumped nearly 53% in premarket trading on Thursday after a late-stage study ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

Shares in ADC Therapeutics were trading down more than 50% today after a non-Hodgkin lymphoma (NHL) trial showed more deaths ...

In a flurry of updates Monday, ADC Therapeutics revealed that it's selling $105 million in new shares while also touting results for antibody-drug conjugate Zynlonta from a small ...

Lonza and Antharis Therapeutics, Inc., a biopharmaceutical company developing next-generation antibody-based therapeutics for ...

Stephens analyst has initiated coverage on ADC Therapeutics SA (NYSE:ADCT), a commercial-stage oncology-focused biotechnology company developing antibody-drug conjugates (ADCs) for patients with ...

Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC” or the “Company”) (NYSE: ADCT). Such investors are ...

Discussion highlights growing importance on novel ADC payloads, and Akari’s ASCO data in KRAS-driven cancers and future ...